HOME >> BIOLOGY >> NEWS
Sitagliptin, a new investigational treatment for type 2 diabetes, may offer new hope for patients

There are currently more than 194 million people with diabetes worldwide and this figure could exceed 333 million by 2025 if untreated. [2] Current treatments for type 2 diabetes are often limited by their side effect profile, route of administration or difficulties in sustaining glucose control. [3] As a result, there is a need for better tolerated treatments that do not cause weight gain and produce less risk of hypoglycaemia for patients with type 2 diabetes. The results of the two Phase II studies indicate that sitagliptin, an investigational diabetes drug, appears to control blood sugar with a low incidence of hypoglycaemia and with a neutral effect on body weight.

In the Phase II studies of more than 1,000 patients, ''sitagliptin'', Merck Sharp & Dohme's investigational medicine from a new class of diabetes treatments called dipeptidyl peptidase 4 (DPP-4) inhibitors, improved glycaemic control in patients with type 2 diabetes and exhibited a safety and tolerability profile similar to placebo. In addition, patients taking sitagliptin experienced no significant weight gain and a low risk of hypoglycaemia.

"Results from the studies conducted to date are very promising," said Peter Stein, Senior Director in Clinical Research, Metabolism, Merck Research Laboratories, Rahway, NJ, USA. "The need for well tolerated therapies which achieve better glycaemic control than current therapies is well known and we are confident that these short-term clinical studies demonstrate proof of concept for sitagliptin, offering a new hope for type 2 diabetes patients. Ongoing Phase III trials should provide greater insight into the efficacy and tolerability profile of sitagliptin over a longer period of time".

Study 1: Effect of sitagliptin oral tablets on glycaemic control
Results from a 12-week, double-blind, placebo-controlled, parallel group study in patients with type 2 diabetes showed that sitagliptin oral tablets significantly r
'"/>

Contact: Catherine Pannell
cpannell@hillandknowlton.com
44-207-413-3059
Merck & Co., Inc.
14-Sep-2005


Page: 1 2 3

Related biology news :

1. FUZEON with investigational HIV drug results in remarkable number of patients achieving undetectable
2. Providence health system shows investigational osteoporosis therapy increases bone mineral density
3. Amgen investigational therapy, AMG 162, increased bone mineral density with twice yearly injection
4. New system of wastewater treatment could reduce the size of treatment plants by half
5. UCF research links proteins, stem cells and potential Alzheimers treatment
6. Geisinger scientist seeks cure for Lou Gehrigs disease, creating device to find treatment
7. System to analyze beating heart stem cells could lead to heart attack treatments
8. Gene expression pattern could lead to improved treatment of pediatric septic shock
9. Molecular detectors may refine cancer treatment
10. First genome-wide study of infectious disease opens new avenues for HIV treatment, vaccines
11. A new method of adult stem cell growth efficacious in treatment of disorders of the cornea

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/1/2017)... BEDFORD, Mass. , March 1, 2017  Aware, ... and services, announced that Richard P. Moberg ... Officer and co-President and Chief Financial Officer and Treasurer ... will continue to serve as a member of the ... T. Russell , Aware,s co-Chief Executive Officer and co-President, ...
(Date:2/27/2017)...   Strategic Cyber Ventures , the industry,s first ... $3.5 million investment in  Polarity , the first commercial ... DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran and ... series A round of funding. This new funding will ...
(Date:2/21/2017)... and PORTLAND, Ore. , ... and the Avamere Family of Companies (Avamere Health Services, ... announced a six-month research study that will apply the ... eldercare at senior living and health centers. By analyzing ... hopes to gain insights into physical and environmental conditions, ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... , ... March 23, 2017 , ... ... recently selected by the Connecticut Technology Council (CTC) as a 2017 Women of ... thirteenth annual Women of Innovation Awards Dinner. , The dinner recognizes women accomplished ...
(Date:3/23/2017)...  Agriculture technology company Cool Planet has closed on ... to commercialize its Cool Terra and Cool Fauna Engineered ... that are simultaneously profitable as well as sustainable and ... months. This latest round of funding was led by ... The company,s primary product, Cool Terra, can improve ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... regeneration from small lab samples to full-size tissues, bones, even whole organs to ... vascular system that delivers blood deep into the developing tissue. , Current ...
(Date:3/22/2017)... , March 22, 2017 Oramed Pharmaceuticals ... www.oramed.com ), a clinical-stage ... drug delivery systems, announced today that Dr. ... deliver a presentation titled, "Oral Insulin for Diabetes ... Cambridge Healthtech Institute,s Oligonucleotide and Peptide Therapeutics (OPT) Boston Conference ...
Breaking Biology Technology:
Cached News: